Nephrotic syndrome, characterized by heavy proteinuria, edema, and hypoalbuminemia, is among the most common chronic kidney diseases of childhood, with an annual incidence of 2.9 (0-6.5) per 100,000 children. 1 In >80% of children, the proteinuria completely remits within 4-6 weeks of corticosteroid therapy, termed steroid-sensitive nephrotic syndrome (SSNS). 2,3Patients with SSNS may show infrequent or frequent relapses but have satisfactory long-term outcomes. 3Lack of complete remission following therapy, termed steroid resistance (SRNS), may be observed at the onset of disease (initial steroid-resistance) or following a relapse (late-resistance), and carries a high risk of disease and therapy-associated complications, including kidney failure. 2Over the past 3 decades, evidence-based guidelines have refined the therapy of nephrotic syndrome.Guidelines on management of nephrotic syndrome were published by the Indian
Sinha et al. (Tue,) studied this question.